Development and evaluation of the rivaroxaban loaded nanostructured lipid carriers for improved oral bioavailability and safety.

ABSTRACT: A recent surge in deep vein thrombosis (DVT) has urged researchers to find potential candidates and new ways of drug delivery to treat the condition. Rivaroxaban (RIVA) is one of the active pharmaceutical agents used to treat DVT due to its unorthodox Xa-inhibiting therapeutic efficacy. However, its poor solubility and toxicity have restricted its therapeutic use. Herein, we prepared RIVA-NLCs to improve the biopharmaceutical performance of the drug. RIVA-NLCs were prepared using high-pressure homogenization and were evaluated based on particle size, zeta potential, polydispersity index, and entrapment efficiency. Differential scanning calorimetry (DSC), X-ray diffractometry (XRD), in vitro release, and in vivo pharmacokinetics studies were performed and compared with the pure drug. Additi

SUBMITTER: Alamri AH 

PROVIDER: S-EPMC12222791 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature